Pipeline news
-
07 August 2019
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2019 . In addition, the Company provided a clinical and business update. As of June 30, 2019 , Syndax had $80.5 million in cash, cash equivalents and short-term investments.
-
10 July 2019
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias.
-
09 July 2019
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.
-
binx health Appoints Healthcare Industry Veteran Gail Marcus to Board of Directors
11 June 2019
binx health, the pioneer in anywhere care in women's health, today announced the appointment of Dr. Gail Marcus to its Board of Directors. Dr. Marcus is an experienced and respected healthcare leader, having held executive positions in multiple healthcare sectors including services, diagnostics, healthcare provision and managed care. Dr. Marcus brings an in-depth understanding of the U.S. healthcare reimbursement environment, as well as strong financial and operational leadership experience to the binx board of directors.
-
03 June 2019
Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, today announced interim data from a Phase 1b trial of the company's lead clinical candidate, zotiraciclib (TG02), in combination with temozolomide (TMZ) for the treatment of recurrent malignant gliomas. The data, which were the subject of a poster presentation at the 2019 ASCO Annual Meeting, identified the optimal dose for zotiraciclib (250mg) in combination with TMZ, with tumor reduction indicating activity and warranting continued investigation.
-
30 May 2019
Epic Sciences, Inc. announced today the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic's CTC technology platform, is published in the Journal of Clinical Oncology Precision Oncology.
-
Epic Sciences Appoints New Chief Technology Officer
22 May 2019
Epic Sciences, Inc. today announced that it has named Chockalingam "Palani" Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive global expansion. In his new role, Dr. Palaniappan will lead the vision for building a globally deployable, regulated platform for routine use of clinical applications for a range of cancer indications, as well as enabling drug discovery in biopharmaceutical industries.
-
Slone Partners Recruits Chief Medical Officer for Epic Sciences
21 May 2019
Executive search firm Slone Partners has placed Richard Wenstrup as the chief medical officer of Epic Sciences. “Dr. Wenstrup’s decades-long experience in oncology leadership and clinical work will add substantial value to Epic Sciences in developing exciting new diagnostic tests that advance the mission of precision medicine,” said Tara Kochis-Stach, president of Slone Partners.
-
17 May 2019
Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, today announced that data from a Phase 1b trial of the company's lead clinical candidate, zotiraciclib (TG02), will be the subject of a poster presentation at the 2019 ASCO Annual Meeting being held in Chicago May 31 to June 4, 2019.
-
Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
15 May 2019
Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and provided a corporate update.
